Jpmorgan Chase & CO Larimar Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,346 shares of LRMR stock, worth $136,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,346

Previous 118,887 84.57%

Holding current value

$136,677

Previous $902,000 85.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$6.33 - $9.89 $636,424 - $994,350	-100,541 Reduced 84.57%	18,346 $133,000
Q1 2024 May 10, 2024	BUY	$4.2 - $13.28 $245,217 - $775,352	58,385 Added 96.5%	118,887 $902,000
Q4 2023 Feb 12, 2024	BUY	$2.35 - $4.71 $77,063 - $154,455	32,793 Added 118.35%	60,502 $275,000
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $105,631 - $153,989	-34,296 Reduced 55.31%	27,709 $109,000
Q2 2023 Aug 11, 2023	SELL	$3.13 - $5.27 $1.91 Million - $3.21 Million	-609,852 Reduced 90.77%	62,005 $194,000
Q1 2023 May 11, 2023	BUY	$4.0 - $6.68 $2.51 Million - $4.19 Million	627,067 Added 1400.02%	671,857 $3.04 Million
Q4 2022 Feb 13, 2023	BUY	$2.73 - $5.08 $119,202 - $221,813	43,664 Added 3877.8%	44,790 $185,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.64 $1,343 - $3,195	-878 Reduced 43.81%	1,126 $4,000
Q2 2022 Aug 11, 2022	SELL	$1.9 - $3.98 $184 - $386	-97 Reduced 4.62%	2,004 $4,000
Q1 2022 May 11, 2022	BUY	$3.65 - $10.84 $1,908 - $5,669	523 Added 33.14%	2,101 $9,000
Q4 2021 Feb 10, 2022	BUY	$8.86 - $13.47 $4,128 - $6,277	466 Added 41.91%	1,578 $17,000
Q3 2021 Nov 12, 2021	BUY	$9.61 - $15.11 $10,686 - $16,802	1,112 New	1,112 $13,000

Others Institutions Holding LRMR

# of Institutions

115

Shares Held

67.7M

Call Options Held

290K

Put Options Held

38.9K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $322M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Larimar Therapeutics, Inc. Transaction History